Skorski T, Kawalec M, Kawiak J
Department of Cytophysiology, Medical Center of Postgraduate Education, Warsaw, Poland.
Bone Marrow Transplant. 1990 Jan;5(1):23-7.
BALB/c x DBA/2 F1 (CD2F1) mice were lethally irradiated and reconstituted with syngeneic bone marrow cells (SBMC) obtained from normal or previously immunized (against L1210 lymphatic leukemia) donors. These recipient mice are called TBI + SBMT or TBI + Imm-SBMT mice, respectively. TBI + Imm-SBMT, but not TBI + SBMT mice, were able to develop strong immune resistance against L1210 leukemia, but not against MOPC 104E plasmacytoma, if the immunization procedure (four i.p. injections at weekly intervals of immunogenic L1210 cells) was started as early as 7 days posttransplantation. Incubation of Imm-SBMC with mafosfamide (ASTA Z7654) before grafting abrogated the ability of the recipient mice to develop early resistance against the leukemia. Treatment of Imm-SBMC with monoclonal or polyclonal antibodies plus complement showed that two or three subpopulations of Imm-SBMC were necessary for the transfer of immune information against leukemia: T lymphocytes with phenotype Thy 1.2+, Lyt 1+2-, I-Ad-, macrophages with phenotype Mac-1+, I-Ad-, and probably asialo-GM 1+ cells. Recipient mice immunized against L1210 leukemia before TBI + SBMT do not develop early resistance to the leukemia.
将BALB/c与DBA/2 F1(CD2F1)小鼠进行致死性照射,并用从正常或先前免疫(针对L1210淋巴白血病)供体获得的同基因骨髓细胞(SBMC)进行重建。这些受体小鼠分别称为TBI + SBMT或TBI + Imm - SBMT小鼠。如果在移植后7天就开始免疫程序(每周腹腔注射4次免疫原性L1210细胞),TBI + Imm - SBMT小鼠而非TBI + SBMT小鼠能够对L1210白血病产生强大的免疫抗性,但对MOPC 104E浆细胞瘤则没有抗性。在移植前用马法兰(ASTA Z7654)孵育Imm - SBMC消除了受体小鼠对白血病产生早期抗性的能力。用单克隆或多克隆抗体加补体处理Imm - SBMC表明,Imm - SBMC的两个或三个亚群对于传递抗白血病免疫信息是必需的:表型为Thy 1.2 +、Lyt 1 + 2 -、I - Ad -的T淋巴细胞,表型为Mac - 1 +、I - Ad -的巨噬细胞,以及可能的脱唾液酸GM 1 +细胞。在TBI + SBMT之前针对L1210白血病进行免疫的受体小鼠不会对白血病产生早期抗性。